NOCI call for projects at EGAM 2009
11 Mar 2009
Translational research is an essential component of the EORTC Scientific Strategy and contributes to the distinction between studies comparing treatment regimes and academically driven studies asking biologically relevant questions. The EORTC scientific strategy places a high priority on the latter, trials with a strong translational research component, and NOCI, a Network of Core Institutions within the EORTC, can facilitate implementation of this scientific strategy. NOCI provides a pan-European network upon which innovative trials with complex designs and translational research requiring specific expertise can be organized. It allows systematic, comprehensive and centralized collection of bio-samples from selected EORTC trials and makes high quality bio-sample collections and associated clinical data sets available to the EORTC network. The NOCI consortium agreement provides a set of general rules for performing NOCI projects including intellectual property, publication, and access rights with the aim of promoting and facilitating research projects and collaborations on translational research.
The NOCI call at EGAM 2009 was conceived to advance EORTC scientific strategy and NOCI projects, in particular, and to foster interaction between the EORTC divisions and the EORTC groups. A session dedicated to this call for NOCI projects will be held on 19 March 2009 from 14.00–19.30 at the EGAM 2009 meeting. The EORTC Board has agreed to allocate up to 1 000 000 euros for this initiative to help launch clinico-genomic trials which cannot be adequately supported by the pharmaceutical industry. Four to five grants are available and will be allocated after final evaluation by EORTC Board. The evaluation criteria include the originality, innovation, and adherence to EORTC scientific strategy, the likely impact of the study on clinical practice, the strength of the translational research component, the appropriateness of the methodology with respect to achieving the study objective, feasibility, and statistical robustness.
Related News
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer
17 May 2026
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026